Researchers test safety of new osteoporosis treatment
The results of a recent study by Japanese researchers revealed that self-applied ViaDerm-hPTH may be effective in treating osteoporosis.
Scientists studied 60 healthy postmenopausal Japanese women, who were given the drug either at the investigational site or self-administered at home for a total of 28 days. ViaDerm was given in transdermal doses - patches applied to the skin - of 30, 50 and 80 grams (g) and compared to daily 20 g injections of Forteo, an existing osteoporosis drug.
The results of the study demonstrate that ViaDerm is safe and well-tolerated, with bone biomarkers dose responses corresponding to the escalating doses of the patches.
"We are very pleased with the results of this study, in which we successfully demonstrated the performance of our new self-applied ViaDerm system as a product intended for home use," said Dr Daphna Heffetz, CEO of TransPharma Medical. "This is an important step towards introducing the ViaDerm system as a household solution for the self-delivery of a variety of medical substances, first and foremost being hPTH for the treatment of osteoporosis."